Although biomarkers of renal damage, such as IL-6, FGF-23 and sST2, have previously been associated with coronary atherosclerosis [18], they were not found to be superior to adropin in patients with early-stage CKD in the present study. The gene discussed is FGF23; the disease is coronary atherosclerosis.